- Shares of Intrexon (XON +1.4%) look to close modestly higher after the company's $26M deal for California-based Medistem (MEDS +47.7%) which develops Endometrial Regenerative Cells.
- XON says the cells "have the potential to provide treatments for conditions such as cancer, wound healing, and cardiovascular disease," when combined with integrated synthetic biology platforms.
- More specifically, XON plans to "develop two powerful classes of clinical products": Engineered stem cells for "therapeutic delivery of secreted proteins" and for "producing exosomes."
- MEDS shareholders are getting $0.27 in cash and "$1.08 worth of XON common stock." (PR)
Intrexon trades higher after Medistem acquisition
Dec 20 2013, 15:55 ET